[1]
|
Samal, B., et al. (1994) Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Molecular and Cellular Biology, 14, 1431-1437.
|
[2]
|
Luk, T., Malam, Z. and Marshall, J.C. (2008) Pre-B cell colony-enhancing factor (PBEF)/visfatin: A novel mediator of innate immunity. Journal of Leukocyte Biology, 83, 804-816. doi:10.1189/jlb.0807581
|
[3]
|
Fukuhara, A., et al. (2005) Visfatin: A protein secreted by visceral fat that mimics the effects of insulin. Science, 307, 426-430. doi:10.1126/science.1097243
|
[4]
|
Li, L., et al. (2006) Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Experimental and Clinical Endocrinology & Diabetes, 114, 544-548. doi:10.1055/s-2006-948309
|
[5]
|
Esteghamati, A., et al. (2011) Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity. Diabetes Research and Clinical Practice, 91, 154-158. doi:10.1016/j.diabres.2010.11.003
|
[6]
|
Filippatos, T.D., et al. (2007) Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome. Journal of Endocrinological Investigation, 30, 323-326.
|
[7]
|
Chen, M.P., et al. (2006) Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. The Journal of Clinical Endocrinology & Metabolism, 91, 295-299.
doi:10.1210/jc.2005-1475
|
[8]
|
McGee, K.C., et al. (2011) Visfatin is regulated by rosiglitazone in type 2 diabetes mellitus and influenced by NFkappaB and JNK in human abdominal subcutaneous adipocytes. PLoS One, 6, e20287.
doi:10.1371/journal.pone.0020287
|
[9]
|
Kadoglou, N.P., et al. (2010) Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus. Metabolism, 59, 373-379. doi:10.1016/j.metabol.2009.08.005
|
[10]
|
Straburzynska-Lupa, A., et al. (2010) Visfatin, resistin, hsCRP and insulin resistance in relation to abdominal obesity in women with rheumatoid arthritis. Clinical and Experimental Rheumatology, 28, 19-24.
|
[11]
|
Stofkova, A., (2010) Resistin and visfatin: Regulators of insulin sensitivity, inflammation and immunity. Endocrine Regulations, 44, 25-36.
doi:10.4149/endo_2010_01_25
|
[12]
|
Samara, A., et al. (2008) Visfatin, low-grade inflammation and body mass index (BMI). Clinical Endocrinology (Oxford), 69, 568-574.
doi:10.1111/j.1365-2265.2008.03205.x
|
[13]
|
Esteghamati, A., et al. (2012) The Value of Visfatin in the Prediction of Metabolic Syndrome: A Multi-Factorial Analysis. Journal of Cardiovascular Translational Research, 5, 541-546. doi:10.1007/s12265-012-9373-8
|
[14]
|
Liu, S.W., (2009) et al. Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clinical Endocrinology (Oxford), 71, 202-207.
doi:10.1111/j.1365-2265.2008.03453.x
|
[15]
|
Zhong, M., et al. (2008) Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clinical Endocrinology (Oxford), 69, 878-884.
doi:10.1111/j.1365-2265.2008.03248.x
|
[16]
|
Chang, Y.H., et al. (2011) Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: A meta-analysis and systemic review. Diabetes Diabetes/Metabolism Research and Reviews, 27, 515-527.
doi:10.1002/dmrr.1201
|
[17]
|
Takebayashi, K., et al. (2007) Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism, 56, 451-458. doi:10.1016/j.metabol.2006.12.001
|
[18]
|
Hammarstedt, A., et al. (2006) Visfatin is an adipokine, but it is not regulated by thiazolidinediones. The Journal of Clinical Endocrinology & Metabolism, 91, 1181-1184.
doi:10.1210/jc.2005-1395
|
[19]
|
Oki, K., et al. (2007) Circulating visfatin level is correlated with inflammation, but not with insulin resistance. Clinical Endocrinology (Oxford), 67, 796-800.
doi:10.1111/j.1365-2265.2007.02966.x
|
[20]
|
Kadoglou, N.P., et al. (2010) Visfatin (nampt) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes. Experimental and Clinical Endocrinology & Diabetes, 118, 75-80.
doi:10.1055/s-0029-1237360
|
[21]
|
Peiro, C., et al. (2010) Visfatin/PBEF/Nampt: A new cardiovascular target? Frontiers in Cardiovascular and Smooth Muscle Pharmacology, 1, 135.
doi:10.3389/fphar.2010.00135
|